| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $92.9M | -19.5% |
| SG&A Expense | $38.6M | -7.6% |
| Operating Income | -$140.9M | +21.5% |
| Pre-tax Income | -$124.5M | +23.0% |
| Income Tax | $0 | — |
| Net Income | -$124.5M | +23.0% |
| EPS (Basic) | -$0.44 | +36.2% |
| EPS (Diluted) | -$0.44 | +36.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $73.8M | +9.0% |
| Short-term Investments | $202.3M | -12.3% |
| Current Assets | $286.2M | -7.3% |
| Total Assets | $396.2M | -21.2% |
| Current Liabilities | $28.5M | -9.2% |
| Total Liabilities | $71.0M | -10.2% |
| Stockholders' Equity | $325.2M | -23.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$95.5M | +12.8% |
| Capital Expenditures | $128K | +113.3% |
| Investing Cash Flow | $100.4M | +164.1% |
| Financing Cash Flow | $1.1M | -99.5% |
| Free Cash Flow | -$95.6M | +12.7% |